CKPT — Checkpoint Therapeutics Share Price
0.000.00%
Last trade - 00:00- $345.11m
- $338.50m
- $0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.56 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8,417.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -137009.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.07 | 0.27 | 0.19 | 0.1 | 0.04 | 41.11 | 185.71 | -52.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
Directors
- Michael Weiss CHM (55)
- James Oliviero PRE (45)
- William Gray CFO (33)
- Lindsay Rosenwald DRC (66)
- Christian Bechon IND (61)
- Scott Boilen IND (54)
- Neil Herskowitz IND (64)
- Barry Salzman IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 10th, 2014
- Public Since
- November 2nd, 2016
- No. of Shareholders
- 64
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 83,763,733
- Address
- 95 SAWYER ROAD, SUITE 110, WALTHAM, 02453
- Web
- https://checkpointtx.com/
- Phone
- +1 7816524500
- Contact
- Ashley Robinson
- Auditors
- KPMG LLP
Upcoming Events for CKPT
Q1 2025 Checkpoint Therapeutics Inc Earnings Release
Checkpoint Therapeutics Inc Extraordinary Shareholders Meeting
Q2 2025 Checkpoint Therapeutics Inc Earnings Release
Similar to CKPT
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Checkpoint Therapeutics share price?
As of Today at 19:53 UTC, shares in Checkpoint Therapeutics are trading at $4.12. This share price information is delayed by 15 minutes.
How has the Checkpoint Therapeutics share price performed this year?
Shares in Checkpoint Therapeutics last closed at $4.12 and the price had moved by +178.38% over the past 365 days. In terms of relative price strength the Checkpoint Therapeutics share price has outperformed the S&P500 Index by +151.02% over the past year.
What are the analyst and broker recommendations for Checkpoint Therapeutics?
The overall consensus recommendation for Checkpoint Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Checkpoint Therapeutics dividend yield?
Checkpoint Therapeutics does not currently pay a dividend.
Does Checkpoint Therapeutics pay a dividend?
Checkpoint Therapeutics does not currently pay a dividend.
When does Checkpoint Therapeutics next pay dividends?
Checkpoint Therapeutics does not currently pay a dividend.
How do I buy Checkpoint Therapeutics shares?
To buy shares in Checkpoint Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Checkpoint Therapeutics?
As of the previous close price of $4.12, shares in Checkpoint Therapeutics had a market capitalisation of $345.11m.
Where are Checkpoint Therapeutics shares listed?
Here are the trading details for Checkpoint Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CKPT
What kind of share is Checkpoint Therapeutics?
Based on an overall assessment of its quality, value and momentum Checkpoint Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Checkpoint Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Checkpoint Therapeutics is $4.33. That is 5.1% above the last closing price of $4.12.
Analysts covering Checkpoint Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.18 for the next financial year.
Find out moreWhat is the trend in the Checkpoint Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Checkpoint Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +17.92%.
As of the last closing price of $4.12, shares in Checkpoint Therapeutics were trading +30.22% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Checkpoint Therapeutics PE Ratio?
The Checkpoint Therapeutics PE ratio based on its reported earnings over the past 12 months is 15.56. The shares last closed at $4.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Checkpoint Therapeutics?
Checkpoint Therapeutics' management team is headed by:
- Michael Weiss - CHM
- James Oliviero - PRE
- William Gray - CFO
- Lindsay Rosenwald - DRC
- Christian Bechon - IND
- Scott Boilen - IND
- Neil Herskowitz - IND
- Barry Salzman - IND